Ira Skvortsova

List of Publications by Year
in descending order

51	2,192	331670	223800
papers	citations	21 h-index	46 g-index

55	55	55	4050
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The role of exosomes in cancer metastasis. Seminars in Cancer Biology, 2017, 44, 170-181.	9.6	305
2	Therapy resistance mediated by cancer stem cells. Seminars in Cancer Biology, 2018, 53, 156-167.	9.6	212
3	The Role of Cancer Stem Cells in Radiation Resistance. Frontiers in Oncology, 2020, 10, 164.	2.8	137
4	Therapy resistance mediated by exosomes. Molecular Cancer, 2019, 18, 58.	19.2	133
5	Radiation resistance: Cancer stem cells (CSCs) and their enigmatic pro-survival signaling. Seminars in Cancer Biology, 2015, 35, 39-44.	9.6	131
6	Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics, 2008, 8, 4521-4533.	2.2	114
7	MPC-6827: A Small-Molecule Inhibitor of Microtubule Formation That Is Not a Substrate for Multidrug Resistance Pumps. Cancer Research, 2007, 67, 5865-5871.	0.9	102
8	Concise Review: Prostate Cancer Stem Cells: Current Understanding. Stem Cells, 2018, 36, 1457-1474.	3.2	90
9	Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Seminars in Cancer Biology, 2015, 31, 36-42.	9.6	80
10	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics, 2021, 11, 7844-7868.	10.0	70
11	Cancer stem cells and their unique role in metastatic spread. Seminars in Cancer Biology, 2020, 60, 148-156.	9.6	68
12	Epithelial-to-mesenchymal transition and c-myc expression are the determinants of cetuximab-induced enhancement of squamous cell carcinoma radioresponse. Radiotherapy and Oncology, 2010, 96, 108-115.	0.6	61
13	Promising Targets in Anti-cancer Drug Development: Recent Updates. Current Medicinal Chemistry, 2018, 24, 4729-4752.	2.4	56
14	Radioresistant head and neck squamous cell carcinoma cells: Intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets. Radiotherapy and Oncology, 2011, 101, 177-182.	0.6	55
15	Pretreatment with Rituximab Enhances Radiosensitivity of Non-Hodgkin's Lymphoma Cells. Journal of Radiation Research, 2005, 46, 241-248.	1.6	54
16	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. Clinical Cancer Research, 2019, 25, 3152-3163.	7.0	53
17	Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials. Current Cancer Drug Targets, 2017, 17, 357-375.	1.6	53
18	Rituximab Enhances Radiation-Triggered Apoptosis in Non-Hodgkin's Lymphoma Cells Via Caspase-dependent and - Independent Mechanisms. Journal of Radiation Research, 2006, 47, 183-196.	1.6	50

#	Article	IF	Citations
19	Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines. European Journal of Cancer, 2005, 41, 2338-2346.	2.8	30
20	Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib. Molecular Cancer Therapeutics, 2009, 8, 1995-2006.	4.1	30
21	Slug Is A Surrogate Marker of Epithelial to Mesenchymal Transition (EMT) in Head and Neck Cancer. Journal of Clinical Medicine, 2020, 9, 2061.	2.4	23
22	Proteomics of cancer stem cells. International Journal of Radiation Biology, 2014, 90, 653-658.	1.8	21
23	Olaparib is effective in combination with, and as maintenance therapy after, firstâ€line endocrine therapy in prostate cancer cells. Molecular Oncology, 2018, 12, 561-576.	4.6	21
24	Rac1 as a multifunctional therapeutic target to prevent and combat cancer metastasis. Oncoscience, 2014, 1, 513-521.	2.2	21
25	Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor. Proteomics - Clinical Applications, 2008, 2, 908-914.	1.6	20
26	Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment. Molecular Cancer Therapeutics, 2004, 3, 1551-8.	4.1	20
27	Targeting Cancer Stem Cells Pathways for the Effective Treatment of Cancer. Current Drug Targets, 2020, 21, 258-278.	2.1	18
28	Effects of Paclitaxel and Docetaxel on EGFR-Expressing Human Carcinoma Cells Under Normoxic Versus Hypoxic ConditionsIn Vitro. Journal of Chemotherapy, 2004, 16, 372-380.	1.5	17
29	Screening and identification of molecular targets for cancer therapy. Cancer Letters, 2017, 387, 3-9.	7.2	16
30	ETV7 regulates breast cancer stem-like cell features by repressing IFN-response genes. Cell Death and Disease, 2021, 12, 742.	6.3	16
31	KLF4, Slug and EMT in Head and Neck Squamous Cell Carcinoma. Cells, 2021, 10, 539.	4.1	14
32	Putative biomarkers and therapeutic targets associated with radiation resistance. Expert Review of Proteomics, 2014, 11, 207-214.	3.0	13
33	Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-ÎºB expression and proteasome activation in head and neck squamous carcinoma cell lines. Molecular Cancer Therapeutics, 2007, 6, 1898-1908.	4.1	11
34	Molecular heterogeneity in breast carcinoma cells with increased invasive capacities. Radiology and Oncology, 2020, 54, 103-118.	1.7	10
35	Pleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and beyond. Cancer Microenvironment, 2019, 12, 67-76.	3.1	9
36	Oxidative damage and cutaneous reactions during radiotherapy in combination with cetuximab. Radiotherapy and Oncology, 2009, 90, 281-282.	0.6	7

#	Article	IF	Citations
37	Editorial. Seminars in Cancer Biology, 2015, 35, 1-2.	9.6	7
38	Feasibility and Toxicity of Concomitant Radio/Immunotherapy with MabThera (RituximabÂ®) for Patients with Non-Hodkin's Lymphoma. Strahlentherapie Und Onkologie, 2011, 187, 300-305.	2.0	6
39	Profilin 1: Do we have a novel proteome-found biomarker predicting response to anticancer therapy?. Proteomics, 2013, 13, 2069-2071.	2.2	6
40	Proteomic approach to understand metastatic spread. Proteomics - Clinical Applications, 2015, 9, 1069-1077.	1.6	6
41	Simvastatin is effective in killing the radioresistant breast carcinoma cells. Radiology and Oncology, 2021, 55, 305-316.	1.7	5
42	Cancer Stem Cells: What Do We Know about Them?. Cells, 2021, 10, 1528.	4.1	5
43	Fractionated Radiation of Primary Prostate Basal Cells Results in Downplay of Interferon Stem Cell and Cell Cycle Checkpoint Signatures. European Urology, 2018, 74, 847-849.	1.9	4
44	Editorial. Seminars in Cancer Biology, 2015, 31, 1-2.	9.6	3
45	Editorial: Recent Trends in Anticancer Drug Development: Challenges and Opportunities. Current Medicinal Chemistry, 2018, 24, 4727-4728.	2.4	3
46	Predicting and Understanding Cancer Response to Treatment. Disease Markers, 2018, 2018, 1-2.	1.3	2
47	Special Issue â€œCancer Stem Cells: Impact on Treatmentâ€• Seminars in Cancer Biology, 2018, 53, iii-iv.	9.6	1
48	In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. Seminars in Cancer Biology, 2018, 52, v-vi.	9.6	1
49	Special Issue â€œEnigmatic tumor properties associated with metastatic spreadâ€•seminars in cancer biology, volume XX. Seminars in Cancer Biology, 2020, 60, iii-iv.	9.6	1
50	EDITORIAL (Hot Topic: â€œSignal Transduction and Response to Anti-Cancer Therapyâ€). Current Signal Transduction Therapy, 2012, 7, 185-186.	0.5	0
51	Editorial (Hot Topic: Cancer Proteomics). Current Proteomics, 2013, 10, 75-75.	0.3	0